Applied Therapeutics, Inc.

NasdaqGM:APLT 주식 보고서

시가총액: US$1.1b

Applied Therapeutics 미래 성장

Future 기준 확인 2/6

Applied Therapeutics은 연간 수입과 매출이 각각 42.1%와 59% 증가할 것으로 예상되고 EPS는 연간 59.3%만큼 증가할 것으로 예상됩니다.

주요 정보

42.1%

수익 성장률

59.3%

EPS 성장률

Biotechs 수익 성장28.4%
매출 성장률59.0%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트20 Nov 2024

최근 미래 성장 업데이트

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16
Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Nov 13
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Aug 11
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24
Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Applied Therapeutics EPS misses by $0.21

Nov 12

수익 및 매출 성장 예측

NasdaqGM:APLT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026155-73N/AN/A3
12/31/202557-88N/AN/A4
12/31/20241-180N/AN/A3
9/30/20240-187-82-82N/A
6/30/20240-161-73-73N/A
3/31/20240-194-67-67N/A
12/31/202310-120-55-55N/A
9/30/202311-97-54-54N/A
6/30/202311-73-59-59N/A
3/31/202311-70-61-61N/A
12/31/2022N/A-83-78-78N/A
9/30/2022N/A-95-89-89N/A
6/30/2022N/A-105-85-85N/A
3/31/2022N/A-105-93-93N/A
12/31/2021N/A-106-91-91N/A
9/30/2021N/A-102-87-87N/A
6/30/2021N/A-104-92-92N/A
3/31/2021N/A-106-82-82N/A
12/31/2020N/A-94-78-78N/A
9/30/2020N/A-88-68-68N/A
6/30/2020N/A-69-55-55N/A
3/31/2020N/A-49-48-48N/A
12/31/2019N/A-46-36-36N/A
9/30/2019N/A-35-30-30N/A
6/30/2019N/A-28-24-24N/A
3/31/2019N/A-23-17-17N/A
12/31/2018N/A-17-11-11N/A

애널리스트 미래 성장 예측

수입 대 저축률: APLT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: APLT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: APLT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: APLT 의 수익(연간 59% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: APLT 의 수익(연간 59% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: APLT 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견